Biohaven Ltd. (BHVN) Stock

Healthcare · Biotechnology · Member of Other US Stocks

Biohaven Ltd. (BHVN) closed at USD 10.93 on 2026-10-14, a change of -36.5 % over the past year, with a market capitalization of USD 1.73B.

Biohaven Ltd. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

Biohaven Ltd. key figures

Previous close

USD 10.93 (2026-10-14)

1-year change

-36.5 %

Market cap

USD 1.73B

Enterprise value

USD 1.76B

P/E ratio (trailing)

-2.45

P/E ratio (forward)

-6.11

EPS (trailing)

-4.66

EPS (forward)

-1.87

PEG ratio

n/a

Price to book

141.11

Revenue growth

n/a

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

6.27

Employees

274

Analyst consensus (third-party)

buy

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About Biohaven Ltd.

Biohaven Ltd., a biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for immunology, neuroscience, and oncology therapeutic areas worldwide. It develops BHV-1300, which is in Phase 2 clinical trial to treat Graves' disease and rheumatoid arthritis; BHV-1400 that is in Phase 2 clinical trial for treating IgA nephropathy; BHV-1600, which is in Phase 1 clinical trial for the treatment of peripartum cardiomyopathy; BHV-8000 that is in Phase 3 clinical trial for treating Parkinson's disease; Opakalim, which is in Phase 3 clinical trial for the treatment of focal epilepsy; BHV-2100 that is in Phase 2 clinical trial for the treatment of pain disorders; and BHV-2000, which is in Phase 2 clinical trial for treating obesity. The company is also developing BHV-1510 that is in Phase 2 clinical trial for the treatment of advanced or metastatic epithelial tumors; and BHV-1530, which is in Phase 2 clinical trial for treating urothelial cancer and other tumors. In addition, its preclinical product pipeline includes BHV-1310 for treating myasthenia gravis; BHV-1320 for treating immune mediated-diseases; BHV-1450 for treating Pemphigus, MuSK MG, and LGI-1 Encephalitis; BHV-1420 for treating membranous nephropathy; BHV-1440 for treating Graves' disease and TED; BHV-6500 for treating type 1 diabetes; BHV-1490 for treating IgM neuropathy and Waldenstrom's; BHV-8100 for treating neurodegenerative diseases; and BHV-1955 for treating tinnitus. The company was formerly known as Biohaven Research Ltd. and changed its name to Biohaven Ltd. in September 2022. Biohaven Ltd. was incorporated in 2022 and is headquartered in New Haven, Connecticut.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for Biohaven Ltd. and compare it with other stocks.